Longitudinal Study of the Porphyrias

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
The American Porphyrias Expert Collaborative
Study ID
NCT01561157
Status
Recruiting

Conditions

  • Acute Porphyrias
  • Cutaneous Porphyrias

Eligibility Criteria

Sex
ALL
Age
1 Minute - N/A
Healthy Volunteers
Not accepted

Study Details

The objective of this protocol is to conduct a longitudinal multidisciplinary investigation of the human porphyrias including the natural history, morbidity, pregnancy outcomes, and mortality in people with these disorders.

Key Dates

Start date
Nov 1, 2010
Status verified
May 2026
Primary completion
Jun 30, 2030
Completion
Jun 30, 2030

Study Design

Enrollment
1,500 participants (estimated)

Arms

  • Arm: Acute Intermittent Porphyria (AIP)
    Patients with a documented diagnosis of AIP
  • Arm: Hereditary Coproporphyria (HCP)
    Patients with a documented diagnosis of HCP
  • Arm: Variegate Porphyria (VP)
    Patients with a documented diagnosis of VP
  • Arm: Congenital Erythropoietic Porphyria (CEP)
    Patients with a documented diagnosis of CEP
  • Arm: Hepatoerythropoietic Porphyria (HEP)
    Patients with a documented diagnosis of HEP
  • Arm: Porphyria Cutanea Tarda (PCT)
    Patients with a documented diagnosis of PCT
  • Arm: Erythropoietic Protoporphyria (EPP)
    Patients with a documented diagnosis of EPP
  • Arm: X-Linked Protoporphyria (XLP)
    Patients with a documented diagnosis of XLP
  • Arm: Aminolevulinate-Dehydratase Deficiency Porphyria (ALAD, ADP)
    Patients with a documented diagnosis of ALAD, ADP
  • Arm: Homozygous Dominant Acute Hepatic Porphyria
    Patients with a documented diagnosis of Homozygous Dominant AHP

Primary Outcome Measure

clinical analysis [ Time Frame: baseline ]

Central Contacts

Locations (16)

FacilityCityStateZIPSite coordinators
University of Alabama, BirminghamBirminghamAlabama35294
Angelina Johnson, RN
205-934-0498
Brendan McGuire, MD (PRINCIPAL_INVESTIGATOR)
University of California, Los AngelesLos AngelesCalifornia90095
Simon Beaven, MD, PhD (PRINCIPAL_INVESTIGATOR)
University of California, San FranciscoSan FranciscoCalifornia94143
Bruce Wang, MD (PRINCIPAL_INVESTIGATOR)
University of MiamiMiamiFlorida33136
Lourdes Olson
Diane Sabogal
Cynthia Levy, MD (PRINCIPAL_INVESTIGATOR)
University of Illinois at ChicagoChicagoIllinois60637
Erin Vidra
312-996-7902
Sean Quigley, MD (PRINCIPAL_INVESTIGATOR)
Massachusetts General HospitalBostonMassachusetts02114
Narmene Bensaber
Amy Dickey, MD (PRINCIPAL_INVESTIGATOR)
University of MinnesotaMinneapolisMinnesota55455
Diondra Howard
Kimberly Dehn
Marshall Mazepa, MD (PRINCIPAL_INVESTIGATOR)
Icahn School of Medicine at Mount SinaiNew YorkNew York10029
Alyne Restrepo
929-626-1096
Manisha Balwani, MD, MS (PRINCIPAL_INVESTIGATOR)
Carolinas Medical Center and HealthCare SystemCharlotteNorth Carolina28203-
Wake Forest University Health SciencesWinston-SalemNorth Carolina27106
Denise Faust
336-713-1442
Sean Rudnick, MD (PRINCIPAL_INVESTIGATOR)
Cleveland ClinicClevelandOhio44195
Angelika Erwin, MD, PhD
Gretchen LaRusch
Angelika Erwin, MD, PhD (PRINCIPAL_INVESTIGATOR)
Thomas Jefferson UniversityPhiladelphiaPennsylvania19107
Manisha Verma
Manish Thapar, MD (PRINCIPAL_INVESTIGATOR)
University of Texas Medical BranchGalvestonTexas77555
Csilla Hallberg, MD
409-772-6287
Karl E. Anderson, MD (PRINCIPAL_INVESTIGATOR)
University of Texas Health Science Center at HoustonHoustonTexas77030
Akshata Moghe, MD, PhD (PRINCIPAL_INVESTIGATOR)
University of UtahSalt Lake CityUtah84132
Hina Yazdani
801-587-2506
John Phillips, PhD (PRINCIPAL_INVESTIGATOR)
University of WashingtonSeattleWashington98195
Sioban Keel, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Birmingham, AL